Tags

Type your tag names separated by a space and hit enter

Entacapone in the management of Parkinson's disease.
Expert Opin Pharmacother. 2002 Jul; 3(7):957-63.EO

Abstract

Entacapone is one of a new class of drugs, the catechol-O-methyltransferase (COMT) inhibitors, which expand the therapeutic options for Parkinson's disease by extending the action of levodopa. Entacapone is used in conjunction with levodopa and provides benefit to patients who suffer from motor fluctuations. Side effects include worsening of the dyskinesias associated with peak doses of levodopa, hypotension, constipation and urine discoloration. Unlike tolcapone, an earlier COMT inhibitor, entacapone does not require liver function monitoring.

Authors+Show Affiliations

The Neurological Institute, Columbia Presbyterian Medical Center, New York, NY 10032, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12083995

Citation

Henchcliffe, Claire, and Cheryl Waters. "Entacapone in the Management of Parkinson's Disease." Expert Opinion On Pharmacotherapy, vol. 3, no. 7, 2002, pp. 957-63.
Henchcliffe C, Waters C. Entacapone in the management of Parkinson's disease. Expert Opin Pharmacother. 2002;3(7):957-63.
Henchcliffe, C., & Waters, C. (2002). Entacapone in the management of Parkinson's disease. Expert Opinion On Pharmacotherapy, 3(7), 957-63.
Henchcliffe C, Waters C. Entacapone in the Management of Parkinson's Disease. Expert Opin Pharmacother. 2002;3(7):957-63. PubMed PMID: 12083995.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Entacapone in the management of Parkinson's disease. AU - Henchcliffe,Claire, AU - Waters,Cheryl, PY - 2002/6/27/pubmed PY - 2002/12/27/medline PY - 2002/6/27/entrez SP - 957 EP - 63 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 3 IS - 7 N2 - Entacapone is one of a new class of drugs, the catechol-O-methyltransferase (COMT) inhibitors, which expand the therapeutic options for Parkinson's disease by extending the action of levodopa. Entacapone is used in conjunction with levodopa and provides benefit to patients who suffer from motor fluctuations. Side effects include worsening of the dyskinesias associated with peak doses of levodopa, hypotension, constipation and urine discoloration. Unlike tolcapone, an earlier COMT inhibitor, entacapone does not require liver function monitoring. SN - 1465-6566 UR - https://www.unboundmedicine.com/medline/citation/12083995/Entacapone_in_the_management_of_Parkinson's_disease_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.3.7.957 DB - PRIME DP - Unbound Medicine ER -